Sonus Pharma (SNUS) ? Opinions Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oliver Ruppert who started this subject	1/16/2001 11:05:34 AM
From: thomas a. burke	of 384

SNUS is trading at book value and well below cash on hand. Today's news represents .21 per share in revenues and possibly more with royalties. It appears to me that SNUS has enough cash on hand and is beginning to generate licensing fees. Could be the beginning of a nice cycle for them. Here is an update on the company: ================================================================================== Financial Summary Sonus Pharmaceuticals is engaged in the research and development of drug delivery systems and oxygen delivery products based on its emulsion and surfactant technology. For the nine months ended 9/30/00, revenues decreased 99% to $113 thousand. Net loss totaled $2.3 million vs. income of $2.4 million. Revenues reflect no payments from collaborative agreements. Net loss reflects the absence of $10 million license payment from Nycomed Amersham. Share-Related Items Market Capitalization $8.02M Shares Outstanding 9.16M Float 5.20M Per-Share Data Book Value (mrq) $0.91 Earnings (ttm) -$0.47 Earnings (mrq) -$0.24 Sales (ttm) $0.01 Cash (mrq) $1.67 ================================================================================== Tom B.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next